TRADITIONAL POSTER - ismrm

Poster Sessions
2193. Characterization of Brain Tumor Using High Order Diffusion Imaging
Chu-Yu Lee 1 , Chris Goettl 2 , Leslie C. Baxter 3 , John P. Karis 3 , Josef P. Debbins, 1,3
1 Electrical Engineering, Arizona State University, Tempe, AZ, United States; 2 College of Medicine, University of Arizona, Phoenix;
3 Barrow Neurological Institute, Phoenix
Brain neoplasms are typically characterized by contrast enhanced T1 imaging. Depending on the course of treatment, tumor reoccurrence remains a
possibility, and can be difficult to distinguish from other enhancing areas, for example post-treatment radiation effects (PTRE), typically necrosis [1].
Further, detailed information about the tumor heterogeneity as detected by standard MR methods is not generally available, but can play a significant role in
characterizing and grading the tumor. In this work, a simple multi-b-value DWI sequence has been developed to better understand the heterogeneity and
diffusion characteristics of different types of tumors, encountered during routine clinical scanning. The signal decay is fitted with two recently developed
diffusion models: a stretched exponential (£\-DWI) [2] and a cumulant expansion (DKI) [3] model, where fitted parameters £\ and Kapp were shown to
correlate the diffusion heterogeneity. We expected to see differences in alpha and K when the multi-b-value DWI sequence directed to the anatomy of
interest, primarily due the heterogeneity of the more advanced tumors.
2194. Tumor Enhancement in a Brain Glioma Model: An Intra-Individual Comparison of Half Dose
Gadobenate Dimeglumine Vs Full Dose Gadopentetate Dimeglumine at 1.5 and 3 T
Ulrike I. Attenberger 1 , Val M. Runge 2 , Jonathan Williams 3 , Henrik J. Michaely
1 Department of Clinical Radiology and Nuclear Medicine, University Medical Center Manheim, Germany, Mannheim, Baden-
Württemberg, Germany; 2 Scott & White Clinic and Hospital, Texas A&M University Health Science Center, Department of
Radiology , Temple, TX, United States; 3 Department of Radiology, , Scott & White Clinic and Hospital, Texas A&M University
Health Science Center, Temple, TX, United States
Regarding nephrogenic systemic fibrosis (NSF), the injected dose level becomes very important, since NSF is reported to be related to gadolinium chelate
injection in patients with an impaired renal function, depending upon chelate stability and dose. With gadobenate dimeglumine, a chelate with transient
protein binding and a higher r1 relaxivity became available. Combining a high relaxivity chelate and 3 T offers multiple opportunities for dose reduction
without loss in image quality. This was proven in a rat brain glioma model at 1.5 and 3 T, comparing half dose gadobenate dimeglumine vs full dose
gadopentetate dimeglumine, a standard extracellular gadolinium chelate.
2195. MRI Acceptance Protocol for the Multicenter GO Glioblastoma Project
Sylvain Ollivro 1,2 , Pierre Antoine Eliat 3 , Eric Hitti, 2,3 , Loan Tran 1 , Jacques Donald de Certaines 1,4 , Hervé
Saint-Jalmes 2,4
1 Cancéropôle Grand Ouest, Rennes, France; 2 LTSI, INSERM, U642, Université Rennes 1, Rennes, France; 3 PRISM, IFR
140/Biogenouest, Université Rennes 1, Rennes, France; 4 CRLCC, Rennes, France
We have verified thanks to a specific common quality control that 7 MRI devices included in a multicenter clinical project, had homogenous and acceptable
characteristics to allow quantification and comparison between parameters extracted from different patient images acquired on different sites and to permit
correlation with biopsies. This quality control was established with sequences from the MRI protocol. The studied parameters slightly varied depending on
the different sites and MRI manufacturers and were in the awaiting of the project. This kind of quality control procedure should be included at the early
beginning of any multicenter clinical projects involving quantitative MRI.
2196. Large Scale Comparison of Gadobenate Dimeglumine and Comparator Agents
Matthew J. Kuhn 1 , Howard A. Rowley 2 , Michael V. Knopp 3 , Kenneth R. Maravilla 4 , Zoran Rumboldt 5
1 Radiology, University of Illinois at Peoria, Peoria, IL, United States; 2 Radiology, University of Wisconsin, Madison, WI, United
States; 3 Radiology, Ohio State University, Columbus, OH, United States; 4 Radiology and Surgery, University of Washington, Seattle,
WA, United States; 5 Radiology, Medical University of South Carolina, Charleston, SC, United States
382 patients were randomized to receive 2 MR exams within 2 days to 2 weeks with equal 0.1mmo/kg doses of either gadobenate dimeglumine (N=382) or a
comparator gadolinium agent. Blinded experts assessed post-contrast images for both qualitative (eg, global contrast enhancement, lesion-to-brain contrast,
lesion delineation, internal lesion morphology and structure, tumor vascularization, and global image preference) and quantitative (eg, contrast-to-noise ratio
[CNR]; percent lesion enhancement) efficacy parameters. In all six studies, images produced following administration of Gd-BOPTA demonstrated greater
contrast enhancement, provided more diagnostic information including additional lesion detection, and were significantly preferred by experienced, blinded
neuroradiologists.